Celcuity Inc. (CELC)
Last updated: 2026-10-21 17:42:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Celcuity Inc. (CELC) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $62.36, with a market capitalization of $2.79B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $53.54 to $151.02. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$2.79B | |
$60.42 | |
$151.02 | |
$4.03 | |
$60.00 | |
596.28K | |
1.20M | |
-- | |
$151.02 | |
$53.54 | |
-- | |
-- |
Celcuity Inc. (CELC) Stock Price Today
Celcuity Inc. (CELC) is currently trading at $62.36 as of 2026-10-21 17:26:59, up 3.93% ($2.36) from the previous close of $60.00
During today's regular trading session, CELC has traded between $4.03 and $151.02, with a trading volume of 596.28K shares. The current price is near the middle of today's range.
Celcuity Inc. (CELC) 7-Day Stock Price Change
Over the past seven days, Celcuity Inc. (CELC) moved from $65.85 to $62.36, representing a decline of 5.30% ($3.49).
The stock traded between $53.54 and $67.52 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 2.36 million shares, up versus the previous seven-day period, indicating higher trading activity.
CELC 52-Week Price Position
Position in Range: 9.0%
CELC is currently trading at $62.36, placing it 9.0% of the way from its 52-week low of $53.54 to its 52-week high of $151.02. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Celcuity Inc. (CELC)?
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Celcuity Inc. Information
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 155 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Celcuity Inc. (CELC) Stock on MEXC
Eligible investors can buy real shares of Celcuity Inc. (CELC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Celcuity Inc. (CELC) stock price today?
2.Is CELC stock going up or down today?
3.What is CELC pre-market price?
4.What is CELC after-hours price?
5.Is CELC stock trading now?
6.Where does CELC sit relative to its 52-week high and low?
7.What sector is Celcuity Inc. in?
8.What is Celcuity Inc.'s market capitalization and where is it listed?
9.How is CELC valued in terms of P/E ratio and EPS?
10.Does Celcuity Inc. pay a dividend?
Explore More US Stocks
Search Stocks
CELC Stock Calculator
Estimate the value between CELC shares and USD.
CELC Shares to USD
1.00 CELC shares = 62.361 USD
Calculations are estimates based on the latest available price and are for reference only.


